Darya-Varia Laboratoria (DVLA) Stock Overview
Manufactures and trades pharmaceutical products and cosmetics in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
DVLA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
PT Darya-Varia Laboratoria Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp1,575.00 |
| 52 Week High | Rp1,715.00 |
| 52 Week Low | Rp1,450.00 |
| Beta | -0.092 |
| 1 Month Change | 4.30% |
| 3 Month Change | -1.56% |
| 1 Year Change | -5.97% |
| 3 Year Change | -21.05% |
| 5 Year Change | -34.38% |
| Change since IPO | 85.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVLA | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -0.3% | 1.6% | 0.4% |
| 1Y | -6.0% | -26.5% | -20.9% |
Return vs Industry: DVLA exceeded the ID Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: DVLA exceeded the ID Market which returned -20.9% over the past year.
Price Volatility
| DVLA volatility | |
|---|---|
| DVLA Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in ID Market | 15.5% |
| 10% least volatile stocks in ID Market | 4.1% |
Stable Share Price: DVLA has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: DVLA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,351 | Ian Martin Kloer | www.darya-varia.com |
PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Consumer Health Products, Prescription Drugs, Export & Toll Manufacturing, and Services. The company offers consumer health products, including skin nutrition products under the Natur-E brand; respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brands for nasal congestion, cough, and breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion.
PT Darya-Varia Laboratoria Tbk Fundamentals Summary
| DVLA fundamental statistics | |
|---|---|
| Market cap | Rp1.76t |
| Earnings (TTM) | Rp136.23b |
| Revenue (TTM) | Rp2.35t |
Is DVLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVLA income statement (TTM) | |
|---|---|
| Revenue | Rp2.35t |
| Cost of Revenue | Rp1.13t |
| Gross Profit | Rp1.22t |
| Other Expenses | Rp1.09t |
| Earnings | Rp136.23b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 121.63 |
| Gross Margin | 51.93% |
| Net Profit Margin | 5.79% |
| Debt/Equity Ratio | 0% |
How did DVLA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/04 18:58 |
| End of Day Share Price | 2026/08/04 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PT Darya-Varia Laboratoria Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.